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Epstein-Barr virus (EBV) ~ shows a  very restricted target cell tropism, in that 
only infection of human and primate B lymphocytes results in establishment of 
continuously growing lymphoblastoid cell lines (LCL) (1, 2). After infection of B 
lymphocytes, the EBV nuclear antigen (EBNA) appears within 10-12 h, cellular 
DNA  synthesis after 40  h,  and  mitosis after 48  h  (3).  An  initial  intracellular 
increase of IgM (K and ~) is seen in the infected cells 40-50 h after infection (4). 2 
B  lymphocytes that express all five Ig classes seem susceptible to infection (5). 
Cell lines derived from cord blood exclusively express IgM and IgD, reflecting 
the phenotypically more  immature lymphocytes circulating in the neonate (6). 
Little is  known about  B  cell  ontogeny in  man.  The  first surface  IgM  (sIgM)- 
positive cells  have  been  identified in  the  fetal liver  as early as  the  9th  wk  of 
gestation (7). Since the bone marrow becomes a site for fetal hematopoeisis after 
the 12th week, the B cell development appears to gradually move from the liver 
to the bone marrow.  In a  recent study (8),  Kamps and Cooper concluded that 
among cells belonging to B cell lineage, ~60 were of sIg- pre-B type in the liver 
and bone marrow of a  12-15-wk-old human fetus. Their study indicates that tile 
first pre-B cell would express only # chain in the cytoplasm, and then light chain, 
before any IgM could be found on the surface. Such cells can still be found in 
the liver and bone marrow of the human fetus before the 30th wk of gestation. 
Since the degree of B cell maturity necessary for EBV infection is not known, 
valuable information regarding the infectability of pre-B cells could be obtained 
by using bone marrow and liver of fetal origin. 
Materials and Methods 
Establishment of Cell Lines.  Bone marrow and, in two cases, liver were obtained from 
14-20-wk-old fetuses after prostaglandin E~-induced abortions within a clinical trial at the 
Karolinska Hospital. Femurs were flushed with RPMI  medium and livers  were gently 
minced with scissors, whereafter single  cell suspensions were centrifuged over a  Ficoll- 
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Isopaque one-step gradient and the  whole mononuclear population was  collected and 
used. The cells were exposed to EBV-B95-8 for 1 h, whereafter they were cultured in 
RPMI  medium  containing  10%  fetal  calf serum  (FCS)  under  standard  tissue  culture 
conditions. Bone marrows from 13 different fetuses were infected, and in all cases EBV- 
positive cell lines were obtained. Uninfected control cultures did not give rise to any cell 
lines.  One line was lost, so we present data on  12 lines, one subclone, and 2 lines from 
fetal liver. The cell lines were considered as established after 3-4 wk in culture, when 
they were given a serial number and designated as follows:  Fe, fetal; BM, bone marrow 
derived; Li, liver derived; E, EBV transformed; 95, derived from B95-8 strain (9) of EBV; 
and Sto, cell lines established at the Department of Tumor Biology, Karolinska Institutet. 
Immunofluorescence Assays.  Presence of surface or intracellular Ig was detected with 
fluorescein isothiocyanate (FITC)-conjugated rabbit  anti-human  heavy or  light  chain- 
specific sera (Dakopatts, Copenhagen) on 5 x  105 live cells (for sIg) or 104 fixed cells on 
cytosmears (intracellular Ig). At least  200 cells  were examined in a  Leitz fluorescence 
microscope, and each cell line was tested in three or more separate experiments. Reactivity 
with the monoclonal antibodies was detected with a fluorescinated second rabbit antibody 
(Litton Bionetics Inc., Kensington, MD), directed against mouse IgM (for LB-1 and BB- 
1) or mouse Ig (for B2). The second antibody was diluted 1:10 with balanced salt solution 
(BSS) in 10% EBV-negative sera. 
Assay for Fc and C3 Receptors.  Presence of Fc and C3 receptors was assayed in parallel 
with standard rosetting techniques using ox erythrocytes (I 0). 
Cloning in Soft Agarose.  The cloning frequency was determined by plating the cells in 
soft agarose as described previously (11). 
Results and Discussion 
In  this paper  we describe  the establishment  and characterization of 12  lym- 
phoblastoid cell  lines  from fetal bone  marrow and  2  from fetal liver, by EBV 
transformation.  The easily identifiable events of the primary infection, appear- 
ance of EBNA and induction of DNA synthesis, showed a pattern similar to that 
in cord blood and adult B  lymphocytes. In these experiments we have used the 
whole heterogenous population of bone marrow cells as targets for the infection. 
The  selection  of immortalized  cells  is  thus  based  on  the  distribution  of EBV 
receptors and sensitivity to virus transformation among these cells. 
There is no information available to allow preselection of stem cells or pre-B 
cells  in  the  human  bone  marrow,  and  nothing  is  yet  known  about  the  EBV 
receptor distribution on such cells. The fresh fetal bone marrow cells that were 
infected consisted of immature hematopoeitic cells, out of which  8-17%  could 
be identified as B cells by their sIgM  expression. Thus, most of the established 
cell lines (I 0/15) carried sIgM with variable levels of sIgD and equal proportions 
of kappa- and lambda-expressing cells (Table I). Since no attempt was made to 
clone the  EBV-infected cells,  except in  one case (FeBM-14-E95-Sto),  the  lines 
are polyclonal as expected. Five cell lines derived from the younger fetuses (_ 16 
wk)  expressed  no  sIg  at  all,  but  all  belonged  to  the  B  cell  lineage,  as  they 
synthesized intracellular  Ig,  either #  chain  alone,  or #  heavy chain and  K or 2~ 
light chain, a pattern characteristic for pre-B cells (Fig.  1 and Table I). 
These cell lines clearly represent at least two major stages in B cell differentia- 
tion; the sIg- pre-B cell and the sIgM+/IgD + fetal B lymphocyte. Among the cell 
lines representing the pre-B cell stage, one of them (FeBM-11-E95-Sto) may be 
of early  pre-B  type,  since  it  expresses  only ~  chain  and  no  light  chain  in  its 
cytoplasm.  As  can  be  seen  in  Table  I,  the  frequency  of positive  cells  varies 
between the lines. There was always a  large proportion of cells scored as Ig-, as 618  EPSTEIN-BARR  VIRUS  TRANSFORMATION  OF  HUMAN  PRE-B  CELLS 
TABLE  I 
Expression of lg in Fetal Bone Marrow Cell Lines 
Age of  Percent slg  ÷ cells*  Percent cytoplasmic 
Cell line  fetus*  lg  + cells 
#  d  "y  a  x  X  ~  K  X 
FeBM-1-E95-STO  18  22-24  0-7  0  0  8-20  14-30  ND  ND  ND 
FeBM-2-E95-STO  16  18-52  5-12  0  0  0-42  4-39  ND  ND  ND 
FeBM-5-E95-STO  20  16-27  7-10  0  0  9-11  10-12  ND  ND  ND 
FeBM-6-E95-STO  20  12-38  4-6  0  0  11-17  13-15  ND  ND  ND 
FeBM-7-E95-STO  20  20-35  4-5  0  0  8-15  8-13  ND  ND  ND 
FeBM-8-E95-STO  16  0  0  0  0  0  0  32  0  25 
FeBM-9-E95-STO  20  13-16  7-14  0  0  8-24  13-14  ND  ND  ND 
FeBM-10-E95-STO  18  7-10  0-6  0  0  2-12  3-9  ND  ND  ND 
FeBM-11-E95-STO  14  0  0  0  0  0  0  13  0 ~  0 
FeBM-12-E95-STO  16  0  0  0  0  0  0  21  0  12 
FeLi- 12-E95-STO  16  0-3  0  0  0  0  0  23  9  0 
FeBM-13-E95-STO  16  0  0  0  0  0  0  26  16  1 
FeLi- 13-E95-STO  16  14  0  0  0  14  2  ND  ND  ND 
FeBM- 14-E95-STO  20  10  1  0  0  11  0  49  18  0 
FeBM- 14-E95-STO clone  20  17-76  13  0  0  0  19-70  9  0  15 
11 
* The ages of the fetuses were estimated according to the following formula (where F  =  length of 
foot in millimeters): [(F +  24)/11] ×  4 =  gestation week. 
* Ranges of the test results are presented. 
§ In one experiment, 6% of the cells stained weakly positive for presence of x-light chains. ND, not 
determined. 
I Clones were obtained by plating, immediately after infection, an average of one cell/well in a 96- 
well microplate.  Established growing clones were harvested and subcultured as described for the 
polyclonal cell lines. 
FIGURE  1.  Micrograph of intracellular immunofluorescence in FeBM-8-E95-Sto, stained for 
presence of #-heavy chains (A) and X-light chains (B). 
judged  from  both  intracellular  and  surface  Ig  staining.  It  is  unlikely,  but  still 
possible,  in  these  polyclonal  lines that  several  "clones"  frozen  at  different  levels 
of  B  differentiation  are  growing  independently  of  each  other.  One  argument 
against  this  is  the  fact  that  the  one  clone  analyzed  (FeBM-14-E95-Sto  clone  1) HANSSON,  FALK,  AND  ERNBERG  619 
TABLE  II 
Exp ressio,  of Various. Su rface Markers a n d Cloning Frequencies on the Feta  I Bone Marrow Cell 
Lines 
Percent positive cells  Cloning 
Cell line  slg*  frequency  I 
LB-I*  BB-I*  B-2*  FcR§  C3R~  (%) 
FeBM- 1-E95-STO  +  70  44  ND  17  69  <2.7 
FeBM-2-E95-STO  +  36  28  ND  0  69  <1.2 
FeBM-5-E95-STO  +  61  53  ND  7  70  <1.3 
FeBM-6-E95-STO  +  58  64  ND  4  84  <0.3 
FeBM-7-E95-STO  +  58  71  ND  13  80  <0.3 
FeBM-9-E95-STO  +  39  53  ND  0  57  <0.9 
FeBM- 10-E95-STO  +  59  31  ND  0  92  <1.1 
FeBM-14-E95-STO  +  70  50  17  0  93  ND 
FeBM-14-E95-STO  clone 1  +  41  56  14  0  93  ND 
FeLi-13-E95-STO  +  ND  ND  5  35  85  ND 
FeBM-8-E95-STO  -  53  37  31  2  77  <0.3 
FeBM- 11-E95-STO  -  44  36  8  I  65  <1.2 
FeBM-12-E95-STO  -  55  21  2  5  70  <1.0 
FeLi- 12-E95-STO  -  52  21  9  7  77  <0.7 
FeBM- 13-E95-STO  -  70  26  4  5  93  <2.1 
* Ig expression according to Table I. 
* Mean percent positive cells of two to three experiments on each cell line. ND, not done. 
t As controls for optimal rosetting conditions,  K562 and Daudi were used in each experiment; they 
were 100% Fc or C3 receptor positive, respectively. 
I As controls in each cloning experiment, the Burkitt line, Raji, was used, showing a cloning frequency 
of 62%; a randomly chosen adult B-LCL was also included,  with a mean cloning efficiency of 3.5%. 
also  contained  negative  cells.  Thus,  there  may be a  variation  of Ig expression 
within  the individual  clones,  whereas  100%  of the cells in all lines were positive 
for the HLA-associated beta-2  microglobulin (data not shown). 
In  vitro  infection  of  adult  peripheral  blood  lymphocyte  (PBL)-derived  B 
lymphocytes with EBV usually results  in an increase  in  Ig synthesis and in some 
cells maturing into Ig-secreting plasma cells (4).  It is possible that the pre-B cells 
in the human  fetus fail to undergo  any differentiation  upon EBV infection due 
to  their  immunoincompetence.  In  the  mouse  system,  information  on  B  cell 
antigens  confined  to stages  of differentiation  is  being obtained  with  the  use  of 
monoclonal antibodies (12). Recently some monoclonal antibodies that recognize 
human  B  cell  antigens  have  become  available;  further  characterization  of our 
EBV-transformed  fetal  lines  has  involved  the  use  of  three  such  monoclonal 
antibodies (Table  II). LB-1  has been described by Youkochi and co-workers (13) 
as  detecting  a  lymphoblastoid  antigen  present  on  LCL  of  B  cell  origin  and 
mitogen-activated  lymphocytes, but not on a  pre-B leukemia (NALM-6), Burkitt 
lymphoma-derived cell lines,  or plasma cell-like  myelomas.  BB-1  shows a  similar 
pattern of reactivity except that it detects a B lymphoblastoid antigen on mitogen- 
activated sIg  + cells and also reacts with Burkitt  lines.  The antigen recognized by 
the other monoclonal, B2, is present on both normal resting B cells and malignant 
early sIg  + B  cells,  but is lost during maturation and is absent on plasma cell-like 
malignancies (14).  Our data suggest that the two antigens detected by LB-1 and 
BB-1 are also induced on the sIg- pre-B cells by EBV transformation  (Table  II), 
but are  not detected  on  fresh  fetal,,BM  cells (data  not shown).  All  the  fetal  cell 620 
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FIGURE 2.  A tentative scheme for B cell differentiation stages. The surface markers such as 
the EBV receptor (Z~), C3-receptor (A), and Ig molecules (Y) are indicated on the cells. Other 
markers that have been identified on cell lines (5,  13-16, this paper) are listed below and the 
presence of a  marker is illustrated with a  solid or dotted  line, whereas absence of the line 
indicates absence of the marker. The fetal cell lines described here are listed at the approximate 
differentiation stages they may represent, together with the Josh cell lines (15) that represent 
earlier stages. The EBV-transformed adult B lymphocytes would, according to this scheme, 
be positioned at the B lymphoblast stages. 
lines tested were positive for both these antigens whether they belonged to the 
slg  + or slg- group (Table Ii).  The  B2 antigen  showed a  much weaker staining 
and  fewer positive  cells  overall  but  no  obvious difference  between  the  more 
immature  lines  and  the  slg  + cell  lines.  The  presence  of Fc  receptors  varied 
among  the  cell  lines  while  the  C3  receptors  that  were tested  in  parallel  were 
strongly expressed on all cell lines (Table II). Although the presence or absence 
of  Fc  receptors  cannot  be  used  to  define  a  certain  maturation  stage,  it  is 
interesting  to  note  that  our  sIg-  cell  lines  all  have  very  low  amounts  of Fc 
receptor-positive cells. This is in contrast to the pre-B cell lines established from 
the patients  with  X-linked  agammaglobulinemia  (X-LA) described by Fu et al. 
(15), which were the most immature lines, of possibly precursor type, and which 
had a high percentage of Fc receptor-positive cells. 
Some EBV-associated Burkitt  lymphoma  tumor  lines are  usually thought  to 
represent an  immature  B cell since they lack slgD and  do not secrete  Ig (16). 
These are highly malignant monoclonal tumors with a high cloning efficiency in 
soft agar.  In vitro transformed peripheral  B lymphocytes have at least a  10-fold 
lower cloning  efficiency (17).  To find out whether  these in  vitro transformed 
fetal  lines  would be  more  "Burkittqike"  because of their  immaturity,  we also 
tested  their  cloning  capacity  in  soft agar  (Table  II).  We  found  no  difference 
between the two groups of fetal cell lines, and they did not differ in their cloning 
capacity from the more mature conventional adult B-LCL. 
In  Fig.  2  we  have  summarized  some  of the  current  information  on  B  cell 
development in man, together with the information on EBV susceptibility gained 
from our study.  It is a  probable assumption  that  the EBV-positive lines (Josh 7 
and Josh :3) from a patient with X-LA that lack both intracellular heavy and light 
chain (15), represent a precursor B cell that is also present in healthy individuals. 
The  next identifiable step in  human  B cell development would be synthesis of 
only intracellular ~ chain, represented by the lines Josh 4 and FeBM-11-E95-Sto. HANSSON,  FALK,  AND  ERNBERG  621 
The establishment of these FeBM lines supports the suggestion by Fu et al. (15) 
that normal pre B cells also can be transformed by EBV. 
Before the pre-B cell matures into a  surface IgM  + B lymphocyte, both heavy 
and  light  chains appear  in  the  cytoplasm.  Fc and  C3  receptors,  although  not 
unique for the B cell lineage, are indicated in Fig. 2 as they appear or disappear 
during  B  cell  ontogeny.  In  addition  to  previous  information  concerning  the 
distribution of antigens detected by monoclonal antibodies and the presence of 
the EBV receptor, we have added the new information that these are also present 
on pre-B  cell  lines.  EBV-transformed fetal cell lines could serve as the normal 
counterpart  to  the  more  often studied  pre-B  cell characteristics  on cells from 
malignancies that affect the B cell lineage. With regard to defining both certain 
cell  surface  markers  and  differentiation steps,  the  transformed  normal  pre-B 
cells are advantageous since many of these malignant cells can not be cultured 
in vitro, a prerequisite for such studies. In conclusion, this study shows that fetal 
bone  marrow  and  liver  contain  cells  that  can  serve  as  targets  for  EBV.  The 
morphology, EBNA expression,  growth pattern, and cloning efficiency in  soft 
agar were similar to that of normal adult B-LCL. Both sIg  ÷ and sIg- B cells have 
the EBV receptor, indicating that the transformed cell lines represent normal B 
cell maturation stages. 
Summary 
In  vitro  infection  of human  B  lymphocytes with  Epstein-Barr  virus  (EBV) 
results in establishment of B lymphoblastoid cell lines that reflect normal B cell 
phenotypes. In this study we have investigated whether immature B cells from 
fetal bone marrow and liver can serve as targets for EBV. The fetal bone marrow 
cells were readily transformed by EBV. Among the resulting cell lines, five were 
surface Ig (sIg)-negative. Three B cell-associated antigens defined by monoclonal 
antibodies were expressed to the same extent on the fetal cell lines, whether they 
belonged to the sIg- or sIg  + group. The various differentiation stages that these 
cell lines may represent are discussed. 
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